Carcinoma in Situ of the Bladder

• CLINICAL_TRIALS trial_result · 2026-04-13
  Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]

  A Phase 2 study is testing pembrolizumab added to intravesical gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer, with the…

• CLINICAL_TRIALS trial_result · 2026-01-14
  Clinical Trial Update: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

  A Phase 1 dose-escalation study of UGN-301 in patients with recurrent non-muscle invasive bladder cancer has been completed.

• CLINICAL_TRIALS trial_result · 2025-11-20
  Clinical Trial Update: A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

  A Phase 1 trial of intravesical Enfortumab Vedotin for non-muscle invasive bladder cancer was terminated, with the study status updated acco…

• CLINICAL_TRIALS trial_result · 2021-06-11
  Clinical Trial Update: Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder [Phase 2]

  Phase 2 trial of durvalumab (Medi4736) for BCG-refractory urothelial carcinoma in situ of the bladder (terminated; results posted).

• CLINICAL_TRIALS trial_result · 2018-03-13
  Clinical Trial Update: RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder [Phase 1, Phase 2]

  This phase 1/2 trial evaluated intravesical gemcitabine in combination with RAD001 (everolimus) for BCG-refractory carcinoma in situ of the …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2015-06-12
  Clinical Trial Update: Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) [Phase 2, Phase 3]

  The document reports the completion status of a Phase 2/3 clinical trial evaluating intravesical valrubicin (AD 32) for carcinoma in situ of…

• CLINICAL_TRIALS trial_result · 2015-02-10
  Clinical Trial Update: Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer [Phase 2]

  Phase 2 study evaluating TMX-101 for carcinoma in situ of the bladder and non-muscle-invasive bladder cancer has completed.

• CLINICAL_TRIALS trial_result · 2014-10-22
  Clinical Trial Update: Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder [Phase 3]

  A Phase 3 trial evaluating maintenance valrubicin versus no maintenance after valrubicin induction in bladder carcinoma in situ; study termi…

• CLINICAL_TRIALS trial_result · 2014-02-19
  Clinical Trial Update: Retrospective Chart Review of Valstar

  A completed retrospective chart review of Valstar for carcinoma in situ of the bladder.